Real-time enrollment status for this tumor-associated hyperinsulinism clinical trial
Current Status
Recruiting
Checked: July 20, 2026 at 5:41 AM UTC
| NCT Number | NCT06881992 |
| Recruiting Status | Recruiting |
| Condition | Tumor-Associated Hyperinsulinism |
| Phase | PHASE3 |
| Target Enrollment | 16 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Rezolute |
| Last Updated on CT.gov | May 18, 2026 (May 18, 2026) |
As of July 20, 2026: Clinical trial NCT06881992 is currently recruiting participants. This phase3 study for tumor-associated hyperinsulinism is actively seeking new participants at 8 locations across the United States. The study is sponsored by Rezolute. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06881992 is actively recruiting participants as of July 20, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06881992 was last updated May 18, 2026 (May 18, 2026). HelloStudys verifies this status automatically.